Enzyme immunoassay for the quantitative determination of Eculizumab (Soliris®) in serum and plasma.

This kit has been especially developed for the quantitative determination of eculizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

Eculizumab Drug Bank Accession Number is DB01257 

Eculizumab is a recombinant humanized monoclonal antibody that targets complement protein C5, preventing cleavage to C5a and C5b, and the formation of the terminal complement complex C5b-9. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions. By the inhibition of this complex, eculizumab is indicated to treat paroxysmal nocturnal hemoglobinuria (PNH) to reduce the risk of complement mediated intravascular hemolysis, to prevent complement mediated microangiopathy in atypical hemolytic uremic syndrome and immune mediated inflammation and damage of the central nervous system in neuromyelitis optica spectrum disorder (NMOSD).

Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

All SHIKARI® ELISA kits are suitable for biosimilar work.

All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.

For technical inquiry, please contact techsupport@matriksbiotek.com

Matriks Biotek® is a biotechnology company that conducts research on biotechnology, developing products and offering its products at a global scale helping people to lead a better life.